Bayer Menopause Drug Meets Key Goal in Late-Stage Trial
By Adria Calatayud
Bayer said investigational drug elinzanetant met its primary goal by reducing symptoms linked to menopause in a late-stage clinical trial, paving the way for submissions to health authorities for approval.
The German pharmaceutical-and-agricultural group said Tuesday that elinzanetant showed a statistically significant reduction in the frequency of moderate to severe vasomotor symptoms, also known as hot flashes, compared to placebo. The long-term safety profile observed over 52 weeks in the phase 3 trial is overall consistent with previously conducted studies, the company said.
The study comes after Bayer reported positive results for two late-stage studies of the same drug.
Bayer said it will submit data from the studies to health authorities for approval of elinzanetant for the treatment of moderate to severe vasomotor symptoms associated with menopause.
Write to Adria Calatayud at adria.calatayud@wsj.com
(END) Dow Jones Newswires
March 19, 2024 03:48 ET (07:48 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?